COVID-19 in Patients With Hematologic Malignancies: A Single Center Retrospective Study

MD, Xuejun Alice Wang,; Binder, Adam; Gergis, Usama; Wilde, Lindsay

doi:10.3389/fonc.2021.740320

Cited by 7 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data confirm that a more significant number of COVID-19 cases were diagnosed with leukemia 63.3%; most of the patients recorded 33 (71.74%) in a survived group with leukemia, however; 13 (28.26%) of the survived patients presented with lymphoma comparatives for 9 (64.29%) in the dead group. This result contradicts the finding of Xuejun et al, Who found that most patients with COVID-19 had lymphoid malignancies 28 . This discrepancy may be due to our regional patient population distribution, which has higher rates of leukemia malignancies.…”

Section: Discussioncontrasting

confidence: 78%

The Impact of Vaccination on Severity of COVID-19 Illness in Hematologic Malignancies Patients

Saleh

Hassan

Zaidan

et al. 2022

View full text Add to dashboard Cite

Covid 19 in hematological cancer patients can lead to a deterioration in the clinical course and a reduction in life expectancy leading high fatality rate. Vaccines developed against the causative virus may reduce the severity of the disease and a decline in mortality rate. This study aims to determine the impact of vaccination on the severity of COVID-19 illness in patients with hematologic malignancies. A multicenter retrospective observational study was conducted on 60 hospitalized patients admitted to intensive care units (ICUs). All patients were previously diagnosed with leukemia or lymphoma and tested positive for COVID-19 by real-time polymerase chain reaction (RT-PCR). Protocol version 8 was used to determine the patients' results, including improvement to discharge criteria or deterioration to death. The most results in this study; The mean age of the patients was 33.63± 16.5 years (range 6-72 years). Diabetes was the most common comorbid illness (10%). The Oxygen saturation range was (70-95%). Among (60) patients enrolled in this study;29(48.33%) was not received any Covid-19 vaccine while 31(51.67%) were fully vaccinated; concerning patients with positive COVID19; the underlying hematological malignancy was leukemia (63.3%) while patients with lymphoma were (36.7%); after 30-day follow up, depending to the outcome. The number of deaths was 14 cases (23.3%) of patients while the other 46 patients (74.7%) survived and were discharged from the hospital. Our study concludes that vaccinating hematological malignancy patients against Covid19 may provide clinical protection from this illness compared to no vaccination patients Keywords. COVID-19 disease, Hematological Malignancy, Vaccine, intensive care units

show abstract

Section: Discussioncontrasting

confidence: 78%

The Impact of Vaccination on Severity of COVID-19 Illness in Hematologic Malignancies Patients

Saleh

Hassan

Zaidan

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Autologous hematopoietic stem cell transplantation (HSCT) for relapsed Hodgkin's lymphoma increases the risk of infection by using intensive chemotherapy [ 3 ]. This risk is ongoing given the increased virulence of severe SARS-CoV-2 [ 4 ]. The Center for International Blood and Marrow Transplant Research (CIBMTR) has concluded that coronavirus infection in patients receiving autologous hematopoietic stem cell transplantation has a poor prognosis [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Prolonged SARS-CoV-2 infection during autologous hematopoietic stem cell transplantation from Hodgkin's lymphoma: a case report

Abakarim¹,

Lahlimi²,

Maghnouj³

et al. 2023

Pan Afr Med J

View full text Add to dashboard Cite

Autologous hematopoietic stem cell transplantation (HSCT) for relapsed Hodgkin's lymphoma increases the risk of infection by using intensive chemotherapy. This risk is obviously ongoing given the increased virulence of severe COVID-19. We report a case of a young man with Hodgkin's lymphoma who received conditioning chemotherapy followed by autologous HSCT and tested positive for SARS-CoV-2 by polymerase chain reaction (PCR) during the early phase of aplasia with persistence of COVID-19 beyond 30 days with favorable follow-up and clinical improvement on treatment. For this type of patient with hematologic malignancy, viral infection can be fatal and strict medical precautions with isolation rules must be maintained, especially for SARS-CoV-2.

show abstract

“…The outbreak of the Coronavirus Disease 19 (COVID-19) began an era of great challenges in the clinical management of patients with hematological malignancies [ 1 ]. In such cases, the immune response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is compromised, thus leading to considerably high morbidity and mortality rates of hematologic patients hospitalized with SARS-CoV-2 infections [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era

Ntanasis-Stathopoulos,

Filippatos,

Gavriatopoulou

et al. 2023

Diseases

View full text Add to dashboard Cite

Background: tixagevimab/cilgavimab, distributed under the name “Evusheld”, was the first available pre-exposure prophylaxis for COVID-19 other than vaccination. It received an EUA from the FDA after sufficient trial data showed efficacy in preventing SARS-CoV-2 infections and subsequent severe disease. Its potential benefits for high-risk immunocompromised patients generated a lot of interest. Individuals with multiple myeloma fall into this category, as they are characterized by attenuated immune responses and, in some cases, vaccines have limited efficacy. Methods: this single-center, prospective study included consecutive patients with multiple myeloma. All individuals were considered high-risk for COVID-19 due to their underlying disease. Baseline demographic and clinical characteristics, as well as data regarding COVID-19 infection and antibodies, were collected. Patients were administered two intramuscular 150 mg doses of Evusheld and were monitored during the follow-up period. Results: one hundred and eleven multiple myeloma patients were included in this analysis, with a median age of 64 years (range 58–69) and fifty-three were females (47.7%). Fourteen patients (12.6%) had a prior history of COVID-19 and all patients were vaccinated with either three or four doses of mRNA-based vaccines. An increase was observed in the median neutralizing-antibody levels before and after tixagevimab/cilgavimab administration, from 92.6% to 97.3%. The high levels were sustainable, with a median neutralizing-antibody level of 95.4% at 3 months post Evusheld administration. Overall, nine patients (8.1%) were diagnosed with COVID-19 during the follow-up period, at a median of 31 days. There were no SARS-CoV-2- infection-related hospitalizations or deaths. The monoclonal antibody combination was well tolerated, with no infusion-related reactions or major adverse events, and pain at the injection site only was reported by 33 patients (30%). Conclusions: tixagevimab/cilgavimab (Evusheld) seemed beneficial for patients with multiple myeloma, who presented high neutralizing-antibody levels and a low incidence of COVID-19 during the initial Omicron wave. No new safety concerns emerged. However, novel combinations of monoclonal antibodies against the new circulating variants of SARS-CoV-2 are deemed necessary in view of the emergence of immune tolerance.

show abstract

COVID-19 in Patients With Hematologic Malignancies: A Single Center Retrospective Study

Cited by 7 publications

References 15 publications

The Impact of Vaccination on Severity of COVID-19 Illness in Hematologic Malignancies Patients

The Impact of Vaccination on Severity of COVID-19 Illness in Hematologic Malignancies Patients

Prolonged SARS-CoV-2 infection during autologous hematopoietic stem cell transplantation from Hodgkin's lymphoma: a case report

Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era

Contact Info

Product

Resources

About